BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27
• 28
• 29
• 30

• Business

  Kala Pharmaceuticals Reports Third Quarter 2017 Financial Results And Provides Business Update

  As of September 30, 2017, Kala had cash of $122.0 million compared to $45.5 million as of December 31, 2016.

  November 7, 2017

   · 

  10 min read
• Business

  Co-Diagnostics Manufacturing Joint Venture Breaks Ground in India

  The facility is expected to be completed in April 2018, at which time CoSara will have the exclusive Indian manufacturing rights for Co-Diagnostics products.

  November 7, 2017

   · 

  2 min read
• Drug Development

  Pique Therapeutics Announces Positive Results in Phase II Clinical Trial of Lead Immunotherapy for Non-Small Cell Lung Cancer

  The Phase II trial was seeking to confirm the safety of PT 107, and further evaluate the efficacy of the drug.

  November 7, 2017

   · 

  3 min read
• Business

  CPHI to Hold Third Quarter 2017 Earnings Conference Call On Wednesday November 15, 2017 at 8:30 a.m. ET

  China Pharma Holdings an NYSE MKT listed corporation with its fully-integrated specialty pharmaceuticals subsidiary based in China, today announced that it plans to hold its third quarter 2017 earnings conference call on Wednesday, November 15, 2017 at 8:30 a.m. ET.

  November 7, 2017

   · 

  1 min read
• Drug Development

  Lycera Presents Tumor Selection Rationale for Phase IIa Study at SITC’s 2017 Annual Meeting for RORgamma Agonist, LYC-55716

  Lycera has selected multiple tumor types, including non-small-cell lung cancer, squamous cell head and neck cancer, ovarian cancer, urothelial cancer, renal cell cancer, and esophageal / gastric cancer for inclusion in the Phase IIa portion of the ARGON study.

  November 7, 2017

   · 

  4 min read
• U.S. Department of Defense Awards Grant to SiteOne Therapeutics, Supporting Research and Development of Selective Small Molecule NaV1.7 Inhibitors as Acute and Chronic Pain Therapeutics

  “There is a critical need for non-opioid therapeutics that treat acute and chronic pain effectively, allowing for less reliance on opioids, and reducing the side effects and addiction potential associated with them.”

  November 7, 2017

   · 

  3 min read
• Business

  Unchained Labs Drifts Into Tokyo, Opens New Office in Japan

  The new Tokyo office, right in the heart of the city, is Unchained Labs’ 6th office worldwide.

  November 7, 2017

   · 

  1 min read
• Drug Development

  Nektar Therapeutics Presents Preclinical Data on NKTR-358, a First-in-Class Regulatory T Cell Stimulator, at 2017 American College of Rheumatology Annual Meeting

  NKTR-358 is a novel immunological therapy designed to target the interleukin receptor complex in the body in order to stimulate proliferation of powerful inhibitory immune cells known as regulatory T cells.

  November 7, 2017

   · 

  7 min read
• Business

  Audentes Therapeutics to Release Third Quarter 2017 Financial Results and Provide Corporate Update on Tuesday, November 14, 2017

  The conference call will be held at 4:30 p.m. ET, after the market closes.

  November 7, 2017

   · 

  1 min read
• FDA

  Aytu BioScience Receives Market Approval From the Australian Therapeutic Goods Administration for the MiOXSYS System for Male Infertility

  MiOXSYS has been approved by the TGA as an aid in the diagnostic assessment of semen quality for patients undergoing male infertility evaluation.

  November 7, 2017

   · 

  4 min read